美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

全球基础设施ETF-iShares

58.11

+0.97001.70%

盘后：58.110.00000.00%16:05 EDT

成交量：43.74万

成交额：2,531.65万

市值：65.08亿

市盈率：- -

高：58.12

开：57.51

低：57.49

收：57.14

数据加载中...

总览公司新闻公告

CESS Network 已通过政府区块链 BMM 一级认证

信达生物IGF-1R抗体药物获批

信达生物(01801)：IGF-1R单抗信必敏获批用于治疗甲状腺眼病

中国首个IGF-1R单抗：信达生物信必敏®获批，填补甲状腺眼病治疗空白

信达生物(01801)：中国首个IGF-1R单抗信必敏®获国家药监局批准上市用于治疗甲状腺眼病

重磅！萨尔瓦多总统计划开采价值3万亿美元的金矿

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/IGF/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IGF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IGF\",,,,,undefined,":{"symbol":"IGF","market":"US","secType":"STK","nameCN":"全球基础设施ETF-iShares","latestPrice":58.11,"timestamp":1747339200000,"preClose":57.14,"halted":0,"volume":437401,"hourTrading":{"tag":"盘后","latestPrice":58.11,"preClose":58.11,"latestTime":"16:05 EDT","volume":248,"amount":14411.28,"timestamp":1747339516335},"delay":0,"floatShares":112000000,"shares":112000000,"eps":0,"marketStatus":"盘后交易","change":0.97,"latestTime":"05-15 18:41:12 EDT","open":57.51,"high":58.12,"low":57.49,"amount":25316475.038914,"amplitude":0.011026,"askPrice":59.99,"askSize":1,"bidPrice":49.86,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1747353600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":57.14,"sharesOutstanding":115800000,"nav":57.073507,"aum":6609112110.6,"bidAskSpread":0.000677,"preHourTrading":{"tag":"盘前","latestPrice":57.15,"preClose":57.14,"latestTime":"09:11 EDT","volume":2065,"amount":118034.745395,"timestamp":1747314682968},"postHourTrading":{"tag":"盘后","latestPrice":58.11,"preClose":58.11,"latestTime":"16:05 EDT","volume":248,"amount":14411.28,"timestamp":1747339516335},"volumeRatio":0.677129,"impliedVol":0.055,"impliedVolPercentile":0.352},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IGF\",,,,,undefined,":{"symbol":"IGF","floatShares":112000000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.677129,"shares":112000000,"dividePrice":1.67905,"high":58.12,"amplitude":0.011026,"preClose":57.14,"low":57.49,"week52Low":47.49,"pbRate":"--","week52High":58.12,"institutionHeld":0,"latestPrice":58.11,"committee":0.980198,"eps":0,"divideRate":0.028894,"volume":437401,"delay":0,"ttmEps":0,"open":57.51,"prevYearClose":52.27,"prevWeekClose":57.34,"prevMonthClose":56.39,"prevQuarterClose":54.67,"fiveDayClose":57.23,"twentyDayClose":54.84,"sixtyDayClose":54.29},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IGF\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531567337","title":"CESS Network 已通过政府区块链 BMM 一级认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2531567337","media":"BitPush","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531567337?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 22:21","pubTimestamp":1745936465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bitpush.news//articles/7422692","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bit_push_live","symbols":["IGF"],"gpt_icon":0},{"id":"2519088875","title":"信达生物IGF-1R抗体药物获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2519088875","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519088875?lang=zh_cn&edition=fundamental","pubTime":"2025-03-14 17:39","pubTimestamp":1741945169,"startTime":"0","endTime":"0","summary":"3月14日，信达生物（01801）发布公告，宣布其研发的IGF-1R抗体信必敏?（替妥尤单抗N01注射液）已获得中国国家药品监督管理局的批准，用于治疗甲状腺眼病。这是中国首个获批的IGF-1R抗体药物，也是全球第二款，标志着该公司在重大疾病治疗领域的又一里程碑。该药物的安全性良好，能够显著改善患者的炎症和生活质量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503143346198629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","LU2488822045.USD","IGF","BK1583","BK1589","LU1969619763.USD","01801","BK1161"],"gpt_icon":0},{"id":"2519821970","title":"信达生物(01801)：IGF-1R单抗信必敏获批用于治疗甲状腺眼病","url":"https://stock-news.laohu8.com/highlight/detail?id=2519821970","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519821970?lang=zh_cn&edition=fundamental","pubTime":"2025-03-14 16:36","pubTimestamp":1741941392,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达生物(01801)宣布，重组抗胰岛素样生长因子1受体（“IGF-1R”）抗体信必敏（替妥尤单抗N01注射液）的新药上市申请（“NDA”）获中国国家药品监督管理局（“NMPA”）批准上市，用于治疗甲状腺眼病(Thyroid Eye Disease,TED)。信必敏是中国首个、全球第二款获批的IGF-1R抗体药物，也是中国甲状腺眼病治疗领域70年来的首款新药，将重塑甲状腺眼病的治疗标准。甲状腺眼病是与甲状腺疾病密切相关的一种器官特异自身免疫性疾病，位居成人眼眶疾病发病率首位，在40-60岁年龄段尤其高发。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/NzJkY2Y1NGFiZmJjZmI1MTMzYzFhNzg2YjE4NjgwNzc5NTAwMDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NzJkY2Y1NGFiZmJjZmI1MTMzYzFhNzg2YjE4NjgwNzc5NTAwMDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1955101","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","01801","LU2328871848.SGD","BK1161","BK1583","IGF","LU2488822045.USD","LU1969619763.USD"],"gpt_icon":0},{"id":"2519356777","title":"中国首个IGF-1R单抗：信达生物信必敏®获批，填补甲状腺眼病治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2519356777","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519356777?lang=zh_cn&edition=fundamental","pubTime":"2025-03-14 16:35","pubTimestamp":1741941300,"startTime":"0","endTime":"0","summary":"信必敏是中国首个、全球第二款获批的IGF-1R抗体药物，也是中国甲状腺眼病治疗领域70年来的首款新药，将重塑甲状腺眼病的治疗标准。信必敏作为中国首个获批的IGF-1R抗体，疗效优异，安全性良好，为甲状腺眼病患者带来了全新可及的治疗选择，具有重要的临床及社会价值。2025年3月，信必敏获中国国家药品监督管理局批准用于治疗甲状腺眼病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4641219_ZH41219_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1589","BK4139","01801","BK1161","LU2328871848.SGD","LU1969619763.USD","BK1583","LU2488822045.USD","IGF","IVBIY"],"gpt_icon":0},{"id":"2519982929","title":"信达生物(01801)：中国首个IGF-1R单抗信必敏®获国家药监局批准上市用于治疗甲状腺眼病","url":"https://stock-news.laohu8.com/highlight/detail?id=2519982929","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519982929?lang=zh_cn&edition=fundamental","pubTime":"2025-03-14 16:34","pubTimestamp":1741941253,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，重组抗胰岛素样生长因子1受体抗体信必敏 的新药上市申请获中国国家药品监督管理局批准上市，用于治疗甲状腺眼病。信必敏是中国首个、全球第二款获批的IGF-1R抗体药物，也是中国甲状腺眼病治疗领域70年来的首款新药，将重塑甲状腺眼病的治疗标准。信必敏作为中国首个获批的IGF-1R抗体，疗效优异，安全性良好，为甲状腺眼病患者带来了全新可及的治疗选择，具有重要的临床及社会价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1261945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","LU2328871848.SGD","01801","IGF","BK1589","BK1583","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2490262885","title":"重磅！萨尔瓦多总统计划开采价值3万亿美元的金矿","url":"https://stock-news.laohu8.com/highlight/detail?id=2490262885","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490262885?lang=zh_cn&edition=fundamental","pubTime":"2024-12-11 14:38","pubTimestamp":1733899081,"startTime":"0","endTime":"0","summary":"萨尔瓦多总统宣称，“我们可能拥有世界上每平方公里最大的金矿。上帝在我们脚下放置了巨大的宝藏，采矿禁令是荒谬的。”","market":"hk","thumbnail":"https://img.jin10.com/gallary/6c56d253-75d4-430c-878f-564a07904fa0.png/lite","type":0,"news_type":0,"thumbnails":["https://img.jin10.com/gallary/6c56d253-75d4-430c-878f-564a07904fa0.png/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=155743&type=news&data_type=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["IGF"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IGF\",params:#limit:5,,,undefined,":[{"date":"2024-12-17","symbol":"IGF","amount":0.84896,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"全球基础设施ETF-iShares","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IGF","amount":0.83009,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"全球基础设施ETF-iShares","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"},{"date":"2023-12-20","symbol":"IGF","amount":0.906875,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares S&P Global Infrastructur","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IGF","amount":0.675429,"announcedDate":"2023-06-06","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares S&P Global Infrastructur","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"},{"market":"US","date":"2022-12-13","symbol":"IGF","amount":0.5179,"defaultRemindTime":1670941800000,"name":"iShares S&P Global Infrastructur","recordDate":"2022-12-19","payableDate":"2022-12-14","currency":"USD","type":"dividend","dateTimestamp":1670907600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IGF\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-24","recordDate":"2015-06-26","paymentDate":"2015-06-30","value":0.529444,"currency":"USD"},{"executeDate":"2015-12-21","recordDate":"2015-12-23","paymentDate":"2015-12-28","value":0.637463,"currency":"USD"},{"executeDate":"2016-06-21","recordDate":"2016-06-23","paymentDate":"2016-06-27","value":0.631518,"currency":"USD"},{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.533733,"currency":"USD"},{"executeDate":"2017-06-20","recordDate":"2017-06-22","paymentDate":"2017-06-26","value":0.735844,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IGF\",market:\"US\",delay:false,,,undefined,":{}}}